Molecular prognostic and predictive factors in cervical cancer

Jayanthi S Lea, Carolyn Y. Muller

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Biomarker studies in preinvasive cervical disease and transition to invasive cancer are geared to understanding the biologic consequence of HPV infection in relation to clinically relevant cervical disease. There are two critical endpoints on the spectrum of cervical dysplasia. (Figure 18.2). The initial point (A) represents the cell at risk due to active HPV infection, whereas the second point (B) represents the clinically relevant preinvasive lesion, cervical intraepithelial neoplasia (CIN) 3 or carcinoma in situ (CIS).The latter lesion is the immediate precursor to invasive cervical cancer (C), and is the target for molecular diagnostic strategies, chemoprevention targeted at reversing aberrant molecular pathways in the preinvasive cells and vaccine strategies aimed at preventing the initiation step.The following sections will highlight some of the progress made in this translational science.

Original languageEnglish (US)
Title of host publicationPrognostic and Predictive Factors in Gynecologic Cancers
PublisherCRC Press
Pages269-280
Number of pages12
ISBN (Electronic)9780203089781
ISBN (Print)9780415391726
StatePublished - Jan 1 2007

Fingerprint

Uterine Cervical Neoplasms
Uterine Cervical Dysplasia
Cervical Intraepithelial Neoplasia
Molecular Pathology
Carcinoma in Situ
Chemoprevention
Infection
Vaccines
Biomarkers
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lea, J. S., & Muller, C. Y. (2007). Molecular prognostic and predictive factors in cervical cancer. In Prognostic and Predictive Factors in Gynecologic Cancers (pp. 269-280). CRC Press.

Molecular prognostic and predictive factors in cervical cancer. / Lea, Jayanthi S; Muller, Carolyn Y.

Prognostic and Predictive Factors in Gynecologic Cancers. CRC Press, 2007. p. 269-280.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lea, JS & Muller, CY 2007, Molecular prognostic and predictive factors in cervical cancer. in Prognostic and Predictive Factors in Gynecologic Cancers. CRC Press, pp. 269-280.
Lea JS, Muller CY. Molecular prognostic and predictive factors in cervical cancer. In Prognostic and Predictive Factors in Gynecologic Cancers. CRC Press. 2007. p. 269-280
Lea, Jayanthi S ; Muller, Carolyn Y. / Molecular prognostic and predictive factors in cervical cancer. Prognostic and Predictive Factors in Gynecologic Cancers. CRC Press, 2007. pp. 269-280
@inbook{981cf51b96eb4893a6915d998fa1f952,
title = "Molecular prognostic and predictive factors in cervical cancer",
abstract = "Biomarker studies in preinvasive cervical disease and transition to invasive cancer are geared to understanding the biologic consequence of HPV infection in relation to clinically relevant cervical disease. There are two critical endpoints on the spectrum of cervical dysplasia. (Figure 18.2). The initial point (A) represents the cell at risk due to active HPV infection, whereas the second point (B) represents the clinically relevant preinvasive lesion, cervical intraepithelial neoplasia (CIN) 3 or carcinoma in situ (CIS).The latter lesion is the immediate precursor to invasive cervical cancer (C), and is the target for molecular diagnostic strategies, chemoprevention targeted at reversing aberrant molecular pathways in the preinvasive cells and vaccine strategies aimed at preventing the initiation step.The following sections will highlight some of the progress made in this translational science.",
author = "Lea, {Jayanthi S} and Muller, {Carolyn Y.}",
year = "2007",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780415391726",
pages = "269--280",
booktitle = "Prognostic and Predictive Factors in Gynecologic Cancers",
publisher = "CRC Press",

}

TY - CHAP

T1 - Molecular prognostic and predictive factors in cervical cancer

AU - Lea, Jayanthi S

AU - Muller, Carolyn Y.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Biomarker studies in preinvasive cervical disease and transition to invasive cancer are geared to understanding the biologic consequence of HPV infection in relation to clinically relevant cervical disease. There are two critical endpoints on the spectrum of cervical dysplasia. (Figure 18.2). The initial point (A) represents the cell at risk due to active HPV infection, whereas the second point (B) represents the clinically relevant preinvasive lesion, cervical intraepithelial neoplasia (CIN) 3 or carcinoma in situ (CIS).The latter lesion is the immediate precursor to invasive cervical cancer (C), and is the target for molecular diagnostic strategies, chemoprevention targeted at reversing aberrant molecular pathways in the preinvasive cells and vaccine strategies aimed at preventing the initiation step.The following sections will highlight some of the progress made in this translational science.

AB - Biomarker studies in preinvasive cervical disease and transition to invasive cancer are geared to understanding the biologic consequence of HPV infection in relation to clinically relevant cervical disease. There are two critical endpoints on the spectrum of cervical dysplasia. (Figure 18.2). The initial point (A) represents the cell at risk due to active HPV infection, whereas the second point (B) represents the clinically relevant preinvasive lesion, cervical intraepithelial neoplasia (CIN) 3 or carcinoma in situ (CIS).The latter lesion is the immediate precursor to invasive cervical cancer (C), and is the target for molecular diagnostic strategies, chemoprevention targeted at reversing aberrant molecular pathways in the preinvasive cells and vaccine strategies aimed at preventing the initiation step.The following sections will highlight some of the progress made in this translational science.

UR - http://www.scopus.com/inward/record.url?scp=85056504212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056504212&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85056504212

SN - 9780415391726

SP - 269

EP - 280

BT - Prognostic and Predictive Factors in Gynecologic Cancers

PB - CRC Press

ER -